MADISON, Wis.--(BUSINESS WIRE)--Puracyp Inc. and Promega Corporation have teamed up to provide all-inclusive kits to assess nuclear receptor activation, P450 metabolism, and cellular toxicity during the drug development process. These whole cell assay systems will identify compounds capable of activating nuclear receptors and inducing P450 metabolism while monitoring for cellular toxicity. The assay kits contain components that have been designed and tested to work together in comprehensive user protocols. Puracyp is contributing their proprietary nuclear receptor expressing cell lines, including cells for measuring human PXR activation by potential therapeutic agents. Promega is bringing its leading assay and detection technologies for bioluminescent reporters, cell viability, and P450-Glo substrate-based metabolism assays.
